Mitsubishi Tanabe Pharma America to Present at XXIX Parkinson's World Congress

Mitsubishi Tanabe Pharma America, Inc. (MTPA) has announced that it will present findings on investigational ND0612 for Parkinson's disease at the International Association of Parkinsonism and Related Disorders (IAPRD) XXIX World Congress in Lisbon, Portugal from May 19-22, 2024. This announcement marks an important milestone in the ongoing research aimed at addressing motor fluctuations in Parkinson's patients.

Gustavo A. Suarez Zambrano, M.D., Vice President of Medical Affairs at MTPA, expressed the company's enthusiasm about sharing recent data from their Phase 3 BouNDless and Phase 2b BeyoND clinical trials. These studies evaluate the effectiveness and safety of ND0612 for Parkinson's patients who suffer from motor fluctuations. According to Zambrano, the participation in IAPRD underscores MTPA's commitment to finding solutions for the challenges faced by those living with Parkinson's disease.

MTPA will present two key posters during an Oral Poster Session scheduled for May 21, 2024, between 9:35 a.m. and 10:20 a.m. WEST. The presentations will highlight results from the Phase 3 BouNDless trial and three-year outcomes from the Phase 2b BeyoND study. These studies focus on the efficacy, safety, and long-term tolerability of ND0612, a continuous subcutaneous infusion of levodopa/carbidopa (LD/CD).

The BouNDless trial (NCT04006210) is a pivotal multi-center, randomized, double-blind double-dummy study. It investigates the impact of ND0612 on motor fluctuations in Parkinson's patients. The BeyoND study (NCT02726386) is an open-label trial that examines the long-term safety and effectiveness of ND0612 in reducing "OFF" time, periods when Parkinson's symptoms are poorly controlled.

Two specific presentations will be made by Dr. Fabrizio Stocchi, M.D., Ph.D., from the Institute for Research and Medical Care (IRCCS) San Raffaele in Rome. The first presentation will cover the efficacy and safety profile of ND0612 from the BouNDless study, while the second will focus on long-term data from the BeyoND study.

ND0612 is an investigational drug-device combination therapy designed to deliver a 24-hour continuous subcutaneous infusion of liquid LD/CD. This treatment aims to address the motor fluctuations experienced by Parkinson's patients. The development of ND0612 is spearheaded by NeuroDerm, Ltd., a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC).

Mitsubishi Tanabe Pharma America, based in Jersey City, N.J., is dedicated to advancing MTPC’s pipeline and commercializing approved pharmaceutical products in North America. Founded in 1678, MTPC is a historical pillar in the pharmaceutical industry, with its headquarters in Osaka, Japan. The company focuses on various disease areas including central nervous system disorders, immuno-inflammation, diabetes, kidney diseases, and cancer. MTPC prioritizes precision medicine and aims to provide highly satisfying treatment options.

NeuroDerm, Ltd., based in Israel, is committed to innovative drug-device combination therapies for central nervous system disorders. As an integrated pharmaceutical and medical technology company, NeuroDerm focuses on reducing disease burden and enhancing the quality of life for patients and their families. The company’s mission aligns with MTPC's broader goals of creating hope for those facing illness.

In summary, MTPA’s upcoming presentations at the IAPRD World Congress will provide valuable insights into the potential of ND0612 to improve the management of Parkinson's disease. These findings could mark a significant step forward in the treatment of motor fluctuations in Parkinson's patients.